Categories
As a Global Breast Cancer Care Council Member, I greatly appreciate the invitation to participate in the Advisory Board Meeting organised by Policy Wisdom and Astra Zeneca on the sidelines of the 2024 American Society of Clinical Oncology Cancer Annual Meeting, which I am currently virtually attending, as it takes place in Chicago, Illinois.
ASCO24 is one of the world’s largest and most prestigious cancer research conferences, with over 40,000 oncology professionals, 200 professional sessions, and more than 5,000 abstracts, focused on the fight against cancer, funded through Conquer Cancer, the ASCO Foundation, a nonprofit organisation created in 1999 to seek dramatic advances in the diagnosis, prevention, treatment, and cure of all types of cancers. Building off of this momentum, the Advisory Board Meeting is bringing together a network of esteemed experts and stakeholders interested in breast cancer, with the aim to validate and refine the preliminary outline of the breast cancer care quality indicator framework.
I am particularly pleased by the results coming out of ASCO, including the promising results from the clinical trials of the cancer drug Enhertu, as it stalled the growth of tumours by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer. This incredibly encouraging news and data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumours that express even the faintest amount of HER2 protein can benefit.
With the goal of learning from and leveraging the research results presented at ASCO, I look forward to advancing efforts in combating breast cancer and improving healthcare outcomes for women in Nigeria and worldwide, fostering a future where every woman has access to the best possible care.
Categories
Recent Posts